Cargando…

Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis

Systemic sclerosis (SSc) is a rare connective tissue disorder characterized by immune dysregulation evoking the pathophysiological triad of inflammation, fibrosis and vasculopathy. In SSc, several alterations in the B-cell compartment have been described, leading to polyclonal B-cell hyperreactivity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graßhoff, Hanna, Fourlakis, Konstantinos, Comdühr, Sara, Riemekasten, Gabriela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496142/ https://www.ncbi.nlm.nih.gov/pubmed/36140251 http://dx.doi.org/10.3390/biomedicines10092150

Ejemplares similares

Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases
por: Graßhoff, Hanna, et al.
Publicado: (2021)

When natural antibodies become pathogenic: autoantibodies targeted against G protein-coupled receptors in the pathogenesis of systemic sclerosis
por: Akbarzadeh, Reza, et al.
Publicado: (2023)

Dysregulation and chronicity of pathogenic T cell responses in the pre-diseased stage of lupus
por: Ohmes, Justus, et al.
Publicado: (2022)

The Lübeck Medication Satisfaction Questionnaire—A Novel Measurement Tool for Therapy Satisfaction
por: Matrisch, Ludwig, et al.
Publicado: (2023)

Autoantibodies targeting neuronal proteins as biomarkers for neurodegenerative diseases
por: Kocurova, Gabriela, et al.
Publicado: (2022)

Advanced Autoantibody Testing in Systemic Sclerosis
por: Almaabdi, Kholoud, et al.
Publicado: (2023)

Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis
por: Kill, Angela, et al.
Publicado: (2014)

Systemic Sclerosis in Zimbabwe: Autoantibody Biomarkers, Clinical, and Laboratory Correlates
por: Sibanda, Elopy N., et al.
Publicado: (2021)

A broad look into the future of systemic sclerosis
por: Riemekasten, Gabriela, et al.
Publicado: (2022)

Therapeutic targets in systemic sclerosis
por: Denton, Christopher P
Publicado: (2007)

Autoantibodies in Systemic Sclerosis: Unanswered Questions
por: Kayser, Cristiane, et al.
Publicado: (2015)

B Cells and Autoantibodies in Multiple Sclerosis
por: Pröbstel, Anne-Katrin, et al.
Publicado: (2015)

New Autoantibody Specificities in Systemic Sclerosis and Very Early Systemic Sclerosis
por: Lande, Roberto, et al.
Publicado: (2021)

Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity
por: Cabral-Marques, Otavio, et al.
Publicado: (2022)

Autoantibodies in Alzheimer’s disease: potential biomarkers, pathogenic roles, and therapeutic implications
por: Wu, Jianming, et al.
Publicado: (2016)

Stress granules and RNA processing bodies are novel autoantibody targets in systemic sclerosis
por: Johnson, Michael E., et al.
Publicado: (2016)

Autoantibody Biomarkers in Rheumatic Diseases
por: Kang, Eun Ha, et al.
Publicado: (2020)

Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients
por: Günther, Jeannine, et al.
Publicado: (2014)

An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod
por: Hesselstrand, Roger, et al.
Publicado: (2021)

Exercise capacity in relation to autoantibodies in systemic sclerosis patients
por: Someya, Fujiko, et al.
Publicado: (2012)

Autoantibodies are present before the clinical diagnosis of systemic sclerosis
por: Burbelo, Peter D., et al.
Publicado: (2019)

Multiparametric autoantibody profiling of patients with systemic sclerosis in Greece
por: Liaskos, Christos, et al.
Publicado: (2018)

Autoantibodies Which Bind to and Activate Keratinocytes in Systemic Sclerosis
por: Moezinia, Carine, et al.
Publicado: (2023)

Autoantibodies as Potential Biomarkers in Breast Cancer
por: Qiu, Jingyi, et al.
Publicado: (2018)

Interleukin-6: a new therapeutic target in systemic sclerosis?
por: O'Reilly, Steven, et al.
Publicado: (2013)

Antigen presentation, autoantibody production, and therapeutic targets in autoimmune liver disease
por: Horst, Andrea Kristina, et al.
Publicado: (2020)

Therapeutic implications of autoantibodies in rheumatoid arthritis
por: Aletaha, Daniel, et al.
Publicado: (2016)

Relevance of Surface Neuronal Protein Autoantibodies as Biomarkers in Seizure-Associated Disorders
por: Stanciu, Gabriela Dumitrita, et al.
Publicado: (2019)

Biomarkers in Systemic Sclerosis: An Overview
por: Di Maggio, Giuseppe, et al.
Publicado: (2023)

α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis
por: Kanno, Yosuke, et al.
Publicado: (2022)

Significance of Autoantibodies to Ki/SL as Biomarkers for Systemic Lupus Erythematosus and Sicca Syndrome
por: Mahler, Michael, et al.
Publicado: (2022)

Autoantibodies associated with neuropsychiatric systemic lupus erythematosus: the quest for symptom-specific biomarkers
por: Sato, Shuzo, et al.
Publicado: (2020)

Comprehensive autoantibody profiles in systemic sclerosis: Clinical cluster analysis
por: Höppner, Jakob, et al.
Publicado: (2023)

Cytokine imbalance in NZB/W mice is associated with autoantibody levels and nephritis
por: Enghard, P, et al.
Publicado: (2004)

Autoantibodies in Serum of Systemic Scleroderma Patients: Peptide-Based Epitope Mapping Indicates Increased Binding to Cytoplasmic Domains of CXCR3
por: Recke, Andreas, et al.
Publicado: (2018)

Specific Autoantibodies and Microvascular Damage Progression Assessed by Nailfold Videocapillaroscopy in Systemic Sclerosis: Are There Peculiar Associations? An Update
por: Hysa, Elvis, et al.
Publicado: (2023)

Increased protease-activated receptor 1 autoantibodies are associated with severe COVID-19
por: Tran, Florian, et al.
Publicado: (2022)

MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis
por: Martinez, Bridget, et al.
Publicado: (2020)

Tumor-associated autoantibodies as diagnostic and prognostic biomarkers
por: Heo, Chang-Kyu, et al.
Publicado: (2012)

MiR-27a as a diagnostic biomarker and potential therapeutic target in systemic sclerosis
por: Bayati, Paria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g45513lopjqe6v9j03jptu5ohl